Literature DB >> 16758367

Effects of milnacipran in animal models of anxiety and memory.

Vânia K M Moojen1, Márcio Rodrigo Martins, Adalisa Reinke, Gustavo Feier, Fabiano R Agostinho, Edson M Cechin, João Quevedo.   

Abstract

Serotonin (5-HT) and noradrenaline (NA) are involved in both pathogenesis and recovery from depression and anxiety. We examined the effects of acute and chronic treatment with milnacipran, a serotonin/noradrenaline reuptake inhibitors (SNRIs) antidepressant, on anxiety and memory retention in rats. Male Wistar rats received acute or chronic administration of milnacipran (12.5, 25 or 50 mg/kg) or saline (control group). The animals were separately submitted to elevated plus-maze, inhibitory avoidance and open-field tasks 1 h after injection, in the acute group, or 23 h after last injection, in the chronic group. Our results showed an anxiolytic-like effect after chronic administration of milnacipran at doses of 25 and 50 mg/kg. The treatment does not interfere in memory retention and habituation to a novel environment at any doses studied. These findings support that milnacipran, an established SNRIs antidepressant, can also be useful in the treatment of anxiety disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16758367     DOI: 10.1007/s11064-006-9050-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  50 in total

1.  Two time windows of anisomycin-induced amnesia for inhibitory avoidance training in rats: protection from amnesia by pretraining but not pre-exposure to the task apparatus.

Authors:  J Quevedo; M R Vianna; R Roesler; F de-Paris; I Izquierdo; S P Rose
Journal:  Learn Mem       Date:  1999 Nov-Dec       Impact factor: 2.460

2.  Adrenoceptor mechanisms underlying imipramine-induced memory deficits in rats.

Authors:  Mohammad Reza Zarrindast; Maryam Ghiasvand; Houman Homayoun; Parvin Rostami; Bijan Shafaghi; Simin Khavandgar
Journal:  J Psychopharmacol       Date:  2003-03       Impact factor: 4.153

Review 3.  A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence.

Authors:  P Blier; C de Montigny; Y Chaput
Journal:  J Clin Psychiatry       Date:  1990-04       Impact factor: 4.384

4.  A schematic representation of the psychopharmacological profile of antidepressants.

Authors:  M Bourin; J P Redrobe; M Hascoet; G B Baker; M C Colombel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1996-11       Impact factor: 5.067

5.  Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report.

Authors:  J B Weilburg; J F Rosenbaum; J Biederman; G S Sachs; M H Pollack; K Kelly
Journal:  J Clin Psychiatry       Date:  1989-12       Impact factor: 4.384

6.  In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed.

Authors:  Jean-Philippe Rénéric; Manuel Bouvard; Luis Stinus
Journal:  Eur Neuropsychopharmacol       Date:  2002-04       Impact factor: 4.600

7.  GABAergic system and imipramine-induced impairment of memory retention in rats.

Authors:  M R Zarrindast; T Shamsi; P Azarmina; P Rostami; B Shafaghi
Journal:  Eur Neuropsychopharmacol       Date:  2004-01       Impact factor: 4.600

Review 8.  Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.

Authors:  Meera Vaswani; Farzana Kadar Linda; Subramanyam Ramesh
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-02       Impact factor: 5.067

9.  Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice.

Authors:  B J Cao; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1998-10       Impact factor: 4.530

10.  Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants.

Authors:  P L Delgado; H L Miller; R M Salomon; J Licinio; G R Heninger; A J Gelenberg; D S Charney
Journal:  Psychopharmacol Bull       Date:  1993
View more
  3 in total

1.  Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia.

Authors:  Robert H Palmer; Antonia Periclou; Pradeep Banerjee
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

2.  Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice.

Authors:  Kinga K Borowicz; Kamila Furmanek-Karwowska; Marta Morawska; Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Psychopharmacology (Berl)       Date:  2009-10-20       Impact factor: 4.530

3.  The noradrenergic symptom cluster: clinical expression and neuropharmacology.

Authors:  Pierre Blier; Mike Briley
Journal:  Neuropsychiatr Dis Treat       Date:  2011-06-03       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.